Viatris, Inc. News
Biogen Beats Third-Quarter Earnings, Cuts Guidance
Drugmaker Biogen's third-quarter results feel the effect of generic versions of its multiple sclerosis treatment.
Mylan Will Buy Aspen Pharmacare's Thrombosis Business
Mylan will acquire drugmaker Aspen Pharmacare's European thrombosis business for $757 million.
Gold, Moderna, Qualtrics, Coronavirus: 5 Things You Must Know
Gold surges to an all-time high amid worsening U.S.-China tensions; Wall Street prepares for a week heavy on tech earnings; Moderna secures an additional $472 million to develop a coronavirus vaccine.
Biogen Stock Off After Barclays Downgrade on Patent Ruling
Biogen is downgraded to equal weight by Barclays, which cited an adverse MS-drug patent ruling.
Biogen Loses Court Decision to Mylan Over Multiple Sclerosis Drug
A U.S. District Court judge rules that Mylan proved claims for Biogen’s patent for Tecfidera are invalid for 'lack of written description.'
State Attorneys General Sue Generic Drugmakers for Inflating Prices
Mylan, Teva, Taro and Perrigo are among those accused of price-fixing, market allocation and bid-rigging on 80 topical drugs.
Gilead Reveals 5 Generic Drugmakers That Will Produce Remdesivir
Gilead announced the drugmakers that will receive non-exclusive voluntary licenses to manufacture remdesivir in 127 countries.
Tesla, Under Armour, Intel, Stage Stores - 5 Things You Must Know Monday
Stock futures suggest a lower start for Wall Street; Under Armour reports earnings; Stage Stores files for bankruptcy.
Johnson & Johnson Stock Lower After Unveiling End To Global Baby Powder Sales In 2023
Johnson & Johnson, which began selling Baby Powder in 1894, will end all sales of the talc-based product next year.
Apple Stock Edges Higher After Report Indicates iPhone Demand Confidence
Apple is asking assemblers to put together 220 million iPhones this year, Bloomberg reported, a tally that largely matches 2021 levels.
Struggling Electric-Truck Maker Nikola Makes a Major Change
Electric-truck manufacturer Nikola, like the broad vehicle industry, has been struggling with supply-chain issues.